WO2002018609A3 - Methods for stable transduction of cells with viral vectors - Google Patents

Methods for stable transduction of cells with viral vectors Download PDF

Info

Publication number
WO2002018609A3
WO2002018609A3 PCT/US2001/027091 US0127091W WO0218609A3 WO 2002018609 A3 WO2002018609 A3 WO 2002018609A3 US 0127091 W US0127091 W US 0127091W WO 0218609 A3 WO0218609 A3 WO 0218609A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
viral vectors
methods
transduced
cell
Prior art date
Application number
PCT/US2001/027091
Other languages
French (fr)
Other versions
WO2002018609A9 (en
WO2002018609A2 (en
Inventor
Laurent Humeau
Wei Han
Xiaobin Lu
Vladimir Stepushkin
Mechelle Lesher
Brian Davis
Yung-Nien Chang
Boro Dropulic
Original Assignee
Virxsys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU8694701A priority Critical patent/AU8694701A/en
Priority to EP01966434A priority patent/EP1315823A2/en
Priority to MXPA03001758A priority patent/MXPA03001758A/en
Priority to NZ524642A priority patent/NZ524642A/en
Priority to AU2001286947A priority patent/AU2001286947B2/en
Priority to JP2002522515A priority patent/JP2004528806A/en
Priority to KR10-2003-7002964A priority patent/KR20030074592A/en
Priority to IL15459901A priority patent/IL154599A0/en
Application filed by Virxsys filed Critical Virxsys
Priority to BR0113619-4A priority patent/BR0113619A/en
Priority to CA2421063A priority patent/CA2421063C/en
Publication of WO2002018609A2 publication Critical patent/WO2002018609A2/en
Publication of WO2002018609A3 publication Critical patent/WO2002018609A3/en
Priority to NO20030901A priority patent/NO20030901L/en
Publication of WO2002018609A9 publication Critical patent/WO2002018609A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The present invention provides methods, as well as compositions related thereto, for the efficient transduction of cells using viral vectors. The efficiency of transduction is increased by contacting the cell to be transduced with one or more molecules that bind the cell surface. Contact with a cell surface binding molecule may occur before, after, or simultaneously with contact between the viral vector and the cell. The transduced vectors may be constructed to express a gene of interest, permitting the transduced cells to be used as therapeutic and prophylactic agents.
PCT/US2001/027091 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors WO2002018609A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR10-2003-7002964A KR20030074592A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
MXPA03001758A MXPA03001758A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors.
NZ524642A NZ524642A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
AU2001286947A AU2001286947B2 (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
JP2002522515A JP2004528806A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells using viral vectors
AU8694701A AU8694701A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
IL15459901A IL154599A0 (en) 2000-08-31 2001-08-29 Methods for transduction of cells with viral vectors
EP01966434A EP1315823A2 (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
BR0113619-4A BR0113619A (en) 2000-08-31 2001-08-29 Methods for stable transduction of viral vector cells.
CA2421063A CA2421063C (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
NO20030901A NO20030901L (en) 2000-08-31 2003-02-26 Methods for stable transduction of cells with viral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/653,088 2000-08-31
US09/653,088 US6627442B1 (en) 2000-08-31 2000-08-31 Methods for stable transduction of cells with hiv-derived viral vectors

Publications (3)

Publication Number Publication Date
WO2002018609A2 WO2002018609A2 (en) 2002-03-07
WO2002018609A3 true WO2002018609A3 (en) 2003-01-16
WO2002018609A9 WO2002018609A9 (en) 2003-08-14

Family

ID=24619453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027091 WO2002018609A2 (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors

Country Status (15)

Country Link
US (2) US6627442B1 (en)
EP (2) EP1315823A2 (en)
JP (1) JP2004528806A (en)
KR (1) KR20030074592A (en)
CN (1) CN100443593C (en)
AU (2) AU2001286947B2 (en)
BR (1) BR0113619A (en)
CA (1) CA2421063C (en)
CZ (1) CZ2003569A3 (en)
IL (1) IL154599A0 (en)
MX (1) MXPA03001758A (en)
NO (1) NO20030901L (en)
NZ (1) NZ524642A (en)
RU (1) RU2280074C2 (en)
WO (1) WO2002018609A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358061A1 (en) * 2000-09-08 2002-03-08 Stemcell Technologies Inc. Novel antibody compositions for the negative selection of specific rat leukocyte subsets
ATE455863T1 (en) * 2001-01-25 2010-02-15 Virxsys Corp METHODS AND COMPOSITIONS FOR IDENTIFYING GENE FUNCTION
US20030121062A1 (en) * 2001-12-21 2003-06-26 Oxford Biomedica (Uk) Limited Transgenic organism
US20040002158A1 (en) * 2002-06-05 2004-01-01 Lung-Ji Chang Long term expression of lentiviral vectors
WO2004044147A2 (en) * 2002-11-07 2004-05-27 Lung-Ji Chang Modified dendritic cells
WO2004069207A2 (en) * 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
BRPI0414970A2 (en) 2003-06-24 2012-12-11 Baxter Int method for transporting drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
CA2537953A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv in humans
WO2005073385A1 (en) * 2004-01-29 2005-08-11 National Institute Of Advanced Industrial Science And Technology Composition and method for elevating gene transfer efficiency
BRPI0510271A (en) 2004-06-15 2007-10-30 Baxter Int Ex vivo applications microparticulate therapeutic agents
AU2005262329A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
CN101374550B (en) * 2004-09-14 2013-05-15 阿戈斯治疗公司 Strain independent amplification of pathogens and vaccines thereto
MX2007010008A (en) 2005-02-16 2008-01-18 Lentigen Corp Lentiviral vectors and their use.
WO2006113622A2 (en) * 2005-04-15 2006-10-26 University Of Maryland, Baltimore Direct vaccination of the bone marrow
AU2006251621A1 (en) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
WO2006130855A2 (en) * 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP2006345852A (en) * 2005-06-16 2006-12-28 Virxsys Corp Antibody conjugate
PT2520168E (en) 2006-07-21 2014-04-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
EP2259798B1 (en) * 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
US9050269B2 (en) * 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
TR201819229T4 (en) * 2009-07-24 2019-01-21 Immune Design Corp Non-integrated lentiviral vectors.
FR2955122B1 (en) * 2010-01-11 2012-09-28 Ct Nat De Rech Scientique ORGANOSPECIFIC FELINE ENDOTHELIAL CELLS AND USES THEREOF.
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
RU2478711C1 (en) * 2011-12-19 2013-04-10 Открытое акционерное общество "Институт стволовых клеток человека" Method for providing higher effectiveness of viral transduction
SG11201403445YA (en) * 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
KR102070472B1 (en) 2012-03-30 2020-01-29 이뮨 디자인 코포레이션 Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20140037599A1 (en) * 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016018664A2 (en) * 2014-07-30 2016-02-04 Texas Tech University System Conditional cytotoxic gene therapy vector for selectable stem cell modification for anti hiv gene therapy
CN104610442B (en) * 2015-01-30 2017-11-24 张永辉 A kind of cell factor particle and its application
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
MA44909A (en) 2015-09-15 2018-07-25 Acerta Pharma Bv THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
KR20180110112A (en) * 2016-02-12 2018-10-08 블루버드 바이오, 인코포레이티드. VCN enhancer composition and method of use thereof
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
CA3021572A1 (en) 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
CA3062450A1 (en) * 2017-05-03 2018-11-08 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
US11584908B2 (en) 2017-09-20 2023-02-21 The Charles Stark Draper Laboratory, Inc. Apparatus for efficient genetic modification of cells
KR20200116076A (en) 2017-10-16 2020-10-08 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Lentiviral vectors for PKLR delivery to treat pyruvate kinase deficiency
JP2021503281A (en) 2017-11-17 2021-02-12 アイオバンス バイオセラピューティクス，インコーポレイテッド TIL expansion culture from fine needle suction and small biopsy
US20210163932A1 (en) 2017-11-22 2021-06-03 Mesoblast International Sárl Cellular compositions and methods of treatment i
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020089411A1 (en) 2018-10-31 2020-05-07 Mesoblast International Sarl Expansion of hematopoietic stem cells
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JOP20210094A1 (en) 2018-11-05 2023-01-30 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
MX2021004953A (en) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Selection of improved tumor reactive t-cells.
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
CN113748202A (en) 2019-03-01 2021-12-03 艾欧凡斯生物治疗公司 Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023506734A (en) 2019-12-11 2023-02-20 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for the production of tumor-infiltrating lymphocytes (TIL) and methods of using same
TW202140790A (en) * 2020-01-22 2021-11-01 愛爾蘭商佧琺藥業有限公司 Method for transducing cells with viral vector
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2023524108A (en) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Selection of improved tumor-reactive T cells
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241468A (en) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4308691A1 (en) 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
TW202327631A (en) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034970A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Improved methods for transfecting t cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
ATE195555T1 (en) * 1994-11-29 2000-09-15 Takara Shuzo Co METHOD FOR PRODUCING TRANSFORMED CELLS
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5885806A (en) 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
ES2153654T3 (en) * 1996-10-17 2001-03-01 Oxford Biomedica Ltd RETROVIRAL VECTORS.
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
EP1414996B1 (en) * 2001-07-10 2010-12-01 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034970A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Improved methods for transfecting t cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COSTELLO B. ET AL.: "GENE TRANSFER INTO STIMULATED AND UNSTIMULATED T LYMPHOCYTES BY HIV-1-DERIVED LENTIVIRAL VECTORS", GENE THERAPY, vol. 7, no. 7, April 2000 (2000-04-01), pages 596 - 604, XP001057677, ISSN: 0969-7128 *
DOUGLAS J. ET AL.: "EFFICIENT TRANSDUCTION OF HUMAN LYMPHOCYTES AND CD34+ CELLS VIA HUMAN IMMUNODEFICIENCY VIRUS-BASED GENE TRANSFER VECTORS", HUMAN GENE THERAPY, vol. 10, no. 6, 10 April 1999 (1999-04-10), pages 935 - 945, XP000891430, ISSN: 1043-0342 *
MOVASSAGH M. ET AL.: "HIGH LEVEL OF RETROVIRUS-MEDIATED GENE TRANSFER INTO DENDRITIC CELLS DERIVED FROM CORD BLOOD AND MOBILIZED PERIPHERAL BLOOD CD34+ CELLS", HUMAN GENE THERAPY, vol. 10, no. 2, 20 January 1999 (1999-01-20), pages 175 - 187, XP000960663, ISSN: 1043-0342 *
NALDINI L. ET AL.: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR", SCIENCE, vol. 272, 12 April 1996 (1996-04-12), pages 263 - 267, XP000583652 *
QUINN E. R. ET AL.: "T CELL ACTIVATION MODULATES RETROVIRUS-MEDIATED GENE EXPRESSION", HUMAN GENE THERAPY, vol. 9, no. 10, 1 July 1998 (1998-07-01), pages 1457 - 1467, XP001057661, ISSN: 1043-0342 *
UCHIDA N. ET AL.: "HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 20, 29 September 1998 (1998-09-29), pages 11939 - 11944, XP002215385, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CZ2003569A3 (en) 2003-11-12
EP2031069A1 (en) 2009-03-04
NO20030901D0 (en) 2003-02-26
WO2002018609A9 (en) 2003-08-14
KR20030074592A (en) 2003-09-19
CA2421063C (en) 2014-05-27
RU2280074C2 (en) 2006-07-20
WO2002018609A2 (en) 2002-03-07
JP2004528806A (en) 2004-09-24
NZ524642A (en) 2007-01-26
IL154599A0 (en) 2003-09-17
US20040062756A1 (en) 2004-04-01
EP1315823A2 (en) 2003-06-04
CN1531596A (en) 2004-09-22
US6627442B1 (en) 2003-09-30
BR0113619A (en) 2004-04-06
RU2003108736A (en) 2005-02-10
MXPA03001758A (en) 2004-11-01
AU8694701A (en) 2002-03-13
CA2421063A1 (en) 2002-03-07
CN100443593C (en) 2008-12-17
AU2001286947B2 (en) 2006-09-07
NO20030901L (en) 2003-04-28

Similar Documents

Publication Publication Date Title
WO2002018609A3 (en) Methods for stable transduction of cells with viral vectors
HK1158696A1 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
WO2006119432A3 (en) Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
WO2001075087A3 (en) Subtilisin variants
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2005017101A3 (en) Avian adenoassociated virus (aaav) and uses thereof
WO2007072056A3 (en) Vectors
WO2002046429A3 (en) Polypeptides having glucoamylase activity and nucleic acids encoding same
DE69942459D1 (en) ISOLATED NUCLEIC ACID MOLECULES COPYING T CELLS INDUCIBLE FACTORS (TIF), ENCODING PROTEINS AND THEIR USE
DK1131444T3 (en) Polypeptides with lysophospholipase activity and nucleic acid encoding them
AU7381098A (en) Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
WO2002014485A3 (en) Kallikrein gene
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
GB0406720D0 (en) Chemical composition and uses
WO2002010393A3 (en) Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
BR0213774A (en) Isolated Nucleic Acid Molecule, Vector, Host Cell, and Method for Preparing a Fine Chemical Compound
WO2002036627A3 (en) Interferons, uses and compositions related thereto
WO2001098469A3 (en) Polypeptides having peroxidase activity and nucleic acids encoding same
WO2003052067A3 (en) Vector mediated organelle transfection
WO2002006508A3 (en) CYCLOMALTODEXTRIN GLUCANOTRANSFERASE (CGTase9, DNA SEQUENCE ENCODING IT AND USES THEREOF
BR0213773A (en) Isolated nucleic acid molecule, vector, host cell, and, method for the preparation of a chemically fine compound
WO2001077348A3 (en) Ketogulonigenium endogenous plasmids
WO2002101072A3 (en) Letm1: modulators of cellular proliferation
WO2002004601A3 (en) Mammalian mdm2 binding proteins and uses thereof
WO2004113539A3 (en) Method for producing a recombinant protein of interest and protein thus produced

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154599

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2003-569

Country of ref document: CZ

Ref document number: 2421063

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001758

Country of ref document: MX

Ref document number: 1020037002964

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002522515

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 524642

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001286947

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001966434

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003108736

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018177255

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001966434

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11

WWP Wipo information: published in national office

Ref document number: 1020037002964

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-569

Country of ref document: CZ